POOR NEUROLEPTIC RESPONSE IN ACUTELY EXACERBATED SCHIZOPHRENIC-PATIENTS

被引:36
作者
SHALEV, A
HERMESH, H
ROTHBERG, J
MUNITZ, H
机构
[1] GEHAH PSYCHIAT HOSP,PETAH TIQWA,ISRAEL
[2] TEL AVIV UNIV,SACKLER SCH MED,TEL AVIV,ISRAEL
[3] WALTER REED ARMY INST RES,DEPT MIL PSYCHIAT,WASHINGTON,DC 20307
关键词
SCHIZOPHRENIA; NEUROLEPTIC DRUG; TREATMENT RESISTANCE;
D O I
10.1111/j.1600-0447.1993.tb03335.x
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Poor neuroleptic response is a major unresolved clinical problem. Precise data concerning the frequency of poor neuroleptic response are not available. The implementation of treatment modalities that are specifically recommended for non-responders (such as clozapine) increases the desirability of such data. This study evaluated the proportion of acutely exacerbated schizophrenics who remained unimproved by consecutive administration of haloperidol, chlorpromazine and perphenazine, in randomly determined order. The overall improvement rate was 95%. The frequency of good responses to the first, second and third drug were 67%, 55%, and 67% respectively. Differences in receptor affinity profile might explain the added beneficial effect of a second or third drug.
引用
收藏
页码:86 / 91
页数:6
相关论文
共 28 条
[1]  
BALDESSARINI RJ, 1984, AM J PSYCHIAT, V141, P748
[2]  
BALDESSARINI RJ, 1988, ARCH GEN PSYCHIAT, V45, P79
[3]  
BIEDERMAN J, 1979, ARCH GEN PSYCHIAT, V36, P327
[4]  
BROMET E, 1974, ARCH GEN PSYCHIAT, V30, P203
[5]   DOPAMINE RECEPTOR-BINDING PREDICTS CLINICAL AND PHARMACOLOGICAL POTENCIES OF ANTI-SCHIZOPHRENIC DRUGS [J].
CREESE, I ;
BURT, DR ;
SNYDER, SH .
SCIENCE, 1976, 192 (4238) :481-483
[6]  
DOUYON R, 1989, AM J PSYCHIAT, V146, P231
[7]  
GOLDSTEIN E, 1972, SOC CASEWORK, V60, P350
[8]   PSYCHIATRIC PATIENTS FAMILY AND LENGTH OF HOSPITALIZATION [J].
GREENLEY, JR .
JOURNAL OF HEALTH AND SOCIAL BEHAVIOR, 1972, 13 (01) :25-37
[9]  
GREENMAN DA, 1989, AM J PSYCHIAT, V146, P226
[10]  
KANE J, 1988, ARCH GEN PSYCHIAT, V45, P789